Key points are not available for this paper at this time.
Treatment with alpelisib-fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer who had received endocrine therapy previously. (Funded by Novartis Pharmaceuticals; SOLAR-1 ClinicalTrials.gov number, NCT02437318.).
Building similarity graph...
Analyzing shared references across papers
Loading...
André et al. (Wed,) studied this question.
www.synapsesocial.com/papers/699ea8a3d8a7e1a4e1facfe4 — DOI: https://doi.org/10.1056/nejmoa1813904
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Fabrice André
Eva Ciruelos
Gábor Rubovszky
New England Journal of Medicine
Massachusetts General Hospital
Inserm
Vanderbilt University
Building similarity graph...
Analyzing shared references across papers
Loading...